Royal Bank Of Canada cut shares of Epizyme, Inc. (NASDAQ:EPZM) from an outperform rating to a sector perform rating in a research note issued to investors on Thursday morning. They currently have $16.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $20.00.

Several other research analysts also recently commented on the company. Zacks Investment Research raised Epizyme from a hold rating to a buy rating and set a $16.00 price target on the stock in a research report on Wednesday, July 12th. BidaskClub downgraded Epizyme from a hold rating to a sell rating in a research report on Wednesday, July 19th. Cann reaffirmed a buy rating and issued a $26.00 price target on shares of Epizyme in a research report on Tuesday, September 19th. Jefferies Group LLC began coverage on Epizyme in a research report on Wednesday, September 20th. They set a buy rating and a $23.00 price objective on the stock. Finally, Oppenheimer Holdings, Inc. restated a buy rating and set a $26.00 price objective on shares of Epizyme in a research report on Tuesday, September 19th. Three analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average target price of $22.67.

Shares of Epizyme (NASDAQ EPZM) traded down $1.95 on Thursday, reaching $14.20. The company’s stock had a trading volume of 685,893 shares, compared to its average volume of 514,189.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.65) by $0.02. equities research analysts predict that Epizyme will post -2.34 EPS for the current year.

WARNING: “Epizyme, Inc. (EPZM) Downgraded to “Sector Perform” at Royal Bank Of Canada” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.watchlistnews.com/epizyme-inc-epzm-downgraded-to-sector-perform-at-royal-bank-of-canada/1678694.html.

In other news, Director David M. Mott bought 200,000 shares of the company’s stock in a transaction dated Monday, September 18th. The stock was bought at an average price of $15.25 per share, for a total transaction of $3,050,000.00. Following the completion of the transaction, the director now directly owns 6,000 shares in the company, valued at approximately $91,500. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Peter Tai-Ching Ho sold 15,000 shares of the business’s stock in a transaction on Thursday, August 24th. The stock was sold at an average price of $15.68, for a total value of $235,200.00. Following the sale, the insider now owns 22,228 shares of the company’s stock, valued at approximately $348,535.04. The disclosure for this sale can be found here. In the last three months, insiders sold 45,000 shares of company stock worth $733,950. Insiders own 25.20% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. Legal & General Group Plc raised its position in shares of Epizyme by 8.9% during the first quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock worth $165,000 after acquiring an additional 795 shares during the last quarter. UBS Asset Management Americas Inc. bought a new stake in shares of Epizyme during the first quarter worth $175,000. Fox Run Management L.L.C. bought a new stake in shares of Epizyme during the third quarter worth $223,000. BB&T Securities LLC bought a new stake in shares of Epizyme during the second quarter worth $181,000. Finally, Trexquant Investment LP bought a new stake in shares of Epizyme during the second quarter worth $184,000. Institutional investors own 72.20% of the company’s stock.

Epizyme Company Profile

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.